PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market Says Frost & Sullivan - New analysis from Frost & Sullivan, European Markets for Parkinson's Disease Therapeutics, finds that the market earned revenues of over $1.28 billion in 2008 and estimates this to reach $2.28 billion in 2015
Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market Says Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2009/12/09 - New analysis from Frost & Sullivan, European Markets for Parkinson's Disease Therapeutics, finds that the market earned revenues of over $1.28 billion in 2008 and estimates this to reach $2.28 billion in 2015.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief. With the introduction of newer dopamine agonists as well as fresh recommendations and treatment guidelines that call for using dopamine agonists as first-line therapy, the market is experiencing a shift away from the use of carbidopa/levodopa.

New analysis from Frost & Sullivan (pharma.frost.com), European Markets for Parkinson's Disease Therapeutics, finds that the market earned revenues of over $1.28 billion in 2008 and estimates this to reach $2.28 billion in 2015.

"Although prescriptions for Sinemet and Sinemet controlled release (CR) continue to be written to a large extent, dopamine agonists prescriptions are increasing as well," says Frost & Sullivan Programme manager Paljit Sohal. "Other drugs account for a relatively small portion of the total prescriptions, while some, such as the catechol-o-methyltransferase (COMT) inhibitors are directly linked with Sinemet prescriptions."

The introduction of Mirapex and Requip has been largely responsible for driving the market over the recent period. The increased use of these medications is spurred by the recent announcements from key physician groups recommending their use in early-stage Parkinson's disease and calling for delay in the use of carbidopa/levodopa due to concerns over the development of clinically relevant dyskinesias.

However, there are considerable chances for physicians to misdiagnose Parkinson's disease. The number of cases that go undiagnosed or misdiagnosed each year range from approximately 20.0 per cent to 40.0 per cent of the total cases. In most cases, the disease is not diagnosed until 80 per cent of the dopamine-producing neurotransmitters are depleted. Earlier diagnosis and treatment has the potential to greatly improve prognosis.

"An estimated one million patients are afflicted with the disease and as many as 4,00,000 are improperly diagnosed or under-diagnosed," explains Ms. Sohal. "Recognising the early signs of the disease and making a referral to a neurologist represent the potential for the disease to go undiagnosed."

Biomarkers and imaging techniques are likely to improve the diagnosis of the condition at a much earlier stage and hence, their development should be supported. High-risk individuals must be identified prior to clinical onset of the disease and disease progression along with response to various therapies should be monitored.

"Market participants should collaborate with neurologists and physicians to improve the rate and the process of diagnosis," concludes Ms. Sohal. "This will expand the target population and thereby, market revenues."

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Katja Feick, Corporate Communications, at katja.feick[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by email.

European Markets for Parkinson's Disease Therapeutics is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European Biosimilars Market Outlook, Eastern Drug Delivery Markets – Opportunity Analysis, and European Lung Cancer Therapeutics Markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.

European Markets for Parkinson's Disease Therapeutics / M32D

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market Says Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Katja Feick 
+49 (0) 69 7703343 katja.feick[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)